[Click eStock] "Neopharm, Export Growth Speed Will Accelerate"

Hana Securities expected that Neopharm's exports would increase next year on the 27th.

Park Eun-jung, a researcher at Hana Securities, explained, "Neopharm is estimated to achieve sales of 130 billion KRW and operating profit of 29.4 billion KRW on a consolidated basis next year," adding, "This represents an increase of 12% and 18%, respectively, compared to this year's expected performance."

She continued, "We expect double-digit growth centered on Zeroid and Real Barrier," and added, "We are focusing on expanding export channels by brand."

Furthermore, she emphasized, "The export ratio is expected to rise from 11% in 2022 to 18% next year," and "Based on the expansion of exports, Neopharm has set a target of over 140 billion KRW in sales and 30 billion KRW in operating profit next year."